NasdaqGS:CLBTSoftware
How the Narrative Surrounding Cellebrite Is Shifting Amid Federal Delays and Future Catalysts
Cellebrite DI's consensus analyst price target has seen a modest uptick, rising from $22.57 to $23.14 despite several headwinds. While lingering softness in the U.S. federal market and revised revenue estimates have tempered enthusiasm, analysts attribute much of this to deal timing delays rather than a loss of demand. Stay tuned to find out how you can track ongoing developments in Cellebrite DI's evolving story.
What Wall Street Has Been Saying
Analyst coverage of Cellebrite DI reflects a...